New fundHealthcare & Life Sciences
Kapiva launches Rs 50 crore innovation fund
By Abha Lohia · Editor ·
Kapiva: revenue and funding and every story →
Founded 2016
- Kapiva sells Ayurvedic supplements, gummies, juices, teas, and skincare with over 100 products
- It commits up to Rs 50 crore for an innovation fund supporting research from early-stage to near-commercialisation
- The fund draws from Kapiva's recent $60 million Series D round, and the company is preparing for an IPO
What happened
- Kapiva has launched an innovation fund with a commitment of up to Rs 50 crore.
- The fund supports projects from early research to near-commercialisation.
- Cheque sizes range from Rs 50 lakh for early-stage research to Rs 4-6 crore for late-stage programmes.
- Focus areas include novel formulations, standardisation, phytochemistry, AI applications in Ayurveda, and clinical studies.
- Eligible applicants are research institutions, PhD scholars, clinicians, hospitals, labs, incubators, and early-stage startups.
- Applications open via a dedicated portal; proposals are evaluated by Kapiva's R&D leadership and external experts.
- Kapiva offers capital, mentorship, access to clinical and research infrastructure, and regulatory guidance.
- Kapiva plans to expand its R&D facility in Bengaluru as part of the initiative.
Why it matters
- The fund aims to make Ayurveda outcome-driven and evidence-backed, according to co-founder Ameve Sharma.
- Capital for the fund is drawn from Kapiva's most recent fundraise – a $60 million Series D round in September 2025.
- Kapiva is preparing for an IPO and plans to go public in the next two to three years.
- The company already runs in-house R&D with clinical trials and collaborates with institutions like THSTI and Manipal Hospitals.
The business
- Kapiva sells Ayurvedic nutrition and wellness products including supplements, gummies, capsules, juices, teas, and skincare.
- It has over 100 products and offers consultations with Ayurvedic doctors.
- Top categories are diabetes care, gym and sports nutrition, energy, liver and heart health; diabetes supplements are the highest-selling.
- Sales channels include a D2C website, online marketplaces, and offline retail stores.
- Kapiva runs in-house R&D with clinical trials on flagship products and a dedicated research team.
- It collaborates with THSTI (Ministry of Science and Technology), Manipal College of Pharmaceutical Sciences, and Manipal Hospitals.
The founders
AS
Ameve Sharma
co-founder- Co-founder of Kapiva.
- Says the innovation fund aims to make Ayurveda outcome-driven and evidence-backed.
SB
Shrey Badhani
co-founder- Co-founded Kapiva.
In numbers
Rs 50 croreFund size commitment · 2026
Rs 50 lakhCheque size for early-stage research · 2026
Rs 4-6 croreCheque size for late-stage programmes · 2026
$120 millionTotal raised to date · 2026
$60 millionSeries D amount · 2025
What happens next
- Kapiva plans to expand its R&D facility in Bengaluru as part of the initiative.
- Kapiva is preparing for an IPO and plans to go public in the next two to three years.
Earlier rounds
- September 2025 · Series D · $60 million · led by 360 ONE Asset and Vertex Growth
Words to know
- phytochemistry
- The study of chemicals derived from plants.
- pre-clinical studies
- Research done before testing on humans, often in labs or on animals.
- clinical studies
- Research involving human volunteers to test treatments or products.
- bioactive enhancement
- Improving the active compounds in a product to make it more effective.
The numbers around it
Healthcare & Life Sciences in January 2026: 12 rounds with a disclosed amount, $99.0 million in all; the biggest was Sukino ($31M). Every sector this year →
Other articles talking about it
Terms in this story
- Funding stage: Startups raise money in steps called funding stages: pre-seed, seed, Series A, B, C and later, ending in a listing or a sale. Each step is larger and asks for more proof. In India, Series A rounds run from a few million dollars to about $15 million, as of November 2026.
- Series B/C: Series B, C, D and later rounds are growth rounds: large cheques for a startup with a proven model that wants to expand, enter new markets or move toward profit and a listing. In India they are usually priced in CCPS and, when foreign investors take part, must follow FEMA pricing rules.
- IPO: An IPO, or initial public offering, is the first time a company sells its shares to the public and lists on a stock exchange. In India SEBI supervises it and the shares trade on the NSE and BSE. A retail investor can bid up to ₹2 lakh, and the issue stays open for three working days.
Read next
LaunchKapiva gives away Dia Free Juice on World Diabetes DayKapiva is a Bengaluru-based Ayurveda wellness brand selling herbal juices and supplements, with a flagship juice aimed at people managing blood sugarFundingAugust AI raises $12M for US expansionAugust AI offers an AI health assistant that answers medical questions through WhatsApp and a mobile appFundingVitusCare raises $3 million Series BVitusCare runs dialysis units inside partner hospitals, which keeps costs low, and has grown from 22 to over 60 centres
Everything on Kapiva → · All startup news on 23 January 2026 →
Is this Kapiva? Get your “Featured on StopDown” badge →